OncoVista Competitors

Pink Sheets USA . 
Stock . OncoVista Innovative Therapies
OncoVista Innovative competes with Cyclacel Pharmaceuticals, Amylyx Pharmaceuticals, Axsome Therapeutics, Exelixis, and Viking Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing OncoVista Innovative competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of OncoVista Innovative to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of OncoVista Innovative competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.00010.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.0000840.00
Details

OncoVista Innovative Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between OncoVista Innovative and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of OncoVista and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of OncoVista Innovative does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
EXEL
+ 0.89
AMLX
MDGL
+ 0.86
EXEL
MDGL
+ 0.63
AMLX
MDGL
+ 0.42
AXSM
EXEL
+ 0.31
AXSM
VKTX
+ 0.24
CYCC
  
High negative correlations   
MDGL
- 0.76
CYCC
EXEL
- 0.73
CYCC
AMLX
- 0.59
CYCC
VKTX
- 0.48
AXSM
MDGL
- 0.35
VKTX
AXSM
- 0.25
CYCC

Risk-Adjusted Indicators

There is a big difference between OncoVista Pink Sheet performing well and OncoVista Innovative Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze OncoVista Innovative's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NTII  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
GNCAQ  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
POLXF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CYCC  5.21 (1.62) 0.00 (3.47) 0.00 
 0.00 
 11.63 
(15.66)
 48.10 
AMLX  4.31  1.40  0.29  1.18  4.02 
(5.11)
 10.06 
(6.13)
 33.56 
AXSM  1.79  0.10  0.03  0.29  1.91 
(2.19)
 4.10 
(3.78)
 13.67 
EXEL  1.45  0.47  0.31  1.04  0.84 
(1.80)
 3.14 
(1.77)
 14.75 
VKTX  3.56 (0.31) 0.00 (0.10) 0.00 
 0.00 
 6.24 
(8.05)
 34.61 
MDGL  2.67  0.52  0.18  1.66  2.10 
(3.67)
 5.17 
(3.96)
 30.27 
All Fundamental Data

OncoVista Innovative Competitive Analysis

The better you understand OncoVista Innovative competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, OncoVista Innovative's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across OncoVista Innovative's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
OVIT NTII POLXF CYCC AMLX AXSM EXEL VKTX MDGL
 0.00 
 0.0001 
OncoVista
 0.00 
 0.0001 
Neurobiological
 0.51 
 1.96 
Polydex
 5.56 
 0.34 
Cyclacel
 7.40 
 5.66 
Amylyx
 1.20 
 97.50 
Axsome
 2.16 
 36.38 
Exelixis
 1.14 
 51.99 
Viking
 0.65 
 345.18 
Madrigal
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very risky
Slightly risky
Very steady
Very steady
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Solid
Modest
Solid
Very Weak
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Dangerous
Dangerous
Very High
Low
Low
Very Low
Below Average
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Buy
Not Available
Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Not Rated
Not Rated
Strong Sell
Hold
Hold
Strong Buy
Strong Sell
Strong Hold
Current Ratio
0.01
N/A
5.88
6.38
7.96
2.44
6.08
11.74
2.55
Net Asset
12.51 K
2.58 M
N/A
8.8 M
517.45 M
588.24 M
2.94 B
368.49 M
640.55 M
Profit Margin
N/A
0.74
-0.25
N/A
-1.32
-0.92
0.22
N/A
N/A
EBITDA
(3.4 M)
19.54 M
(568.16 K)
(25.42 M)
39.89 M
(224.99 M)
196.6 M
(100.83 M)
(379.97 M)
Current Valuation
852.92 K
(26.24 M)
2.23 M
(743.76 K)
156.15 M
4.65 B
9.17 B
4.93 B
6.65 B
Price To Book
26.09
0.0655
0.42
2.02
1.98
51.48
4.47
6.43
9.69
Operating Margin
N/A
0.77
-0.22
-911.0
-181.88
-0.44
0.35
N/A
-1.87
Retained Earnings
(27.6 M)
N/A
(19.53 M)
(428.28 M)
(304.95 M)
(835.57 M)
(173.35 M)
(377.94 M)
(1.34 B)
Current Asset
61 K
N/A
3.41 M
24.57 M
N/A
34.76 M
178.66 M
15.2 M
363.58 K
Beta
-51.97
-408.27
0.33
0.56
-0.7
1.25
0.51
0.99
-0.47
Number Of Employees
2
4
21
7
384
607
1.31 K
30
376
Equity Positions Weight
N/A
N/A
N/A
N/A
50.03
N/A
N/A
N/A
N/A
Shares Outstanding
23.56 M
27.02 M
3.43 M
6.29 M
68.55 M
48.46 M
285.58 M
111.44 M
21.81 M
Cash Flow From Operations
(232.38 K)
4.78 M
(238.54 K)
(16.11 M)
11.92 M
(145.08 M)
333.32 M
(73.38 M)
(324.23 M)
Total Debt
479.3 K
N/A
301.49 K
37 K
4.24 M
186.37 M
189.94 M
1.26 M
117.19 M
Return On Equity
N/A
1.0
-0.18
-5.71
-0.84
-1.72
0.2
-0.15
-1.3
Z Score
N/A
27.29
1.4
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-23.58
N/A
-0.0824
-1.03
-0.43
-0.26
0.13
-0.13
-0.52
Book Value Per Share
-0.28
1.07
1.44
0.57
2.86
1.92
7.96
8.18
35.64
Number Of Shares Shorted
N/A
37.6 K
11
66.77 K
1.29 M
7.58 M
9.12 M
13.28 M
4.53 M
Current Liabilities
5.95 M
73 K
1.28 M
5.75 M
N/A
6.74 M
52.25 M
1.98 M
49.28 M
Total Asset
12.51 K
2.58 M
6.56 M
8.8 M
517.45 M
588.24 M
2.94 B
368.49 M
640.55 M
Short Ratio
N/A
0.09
0.02
0.03
0.81
18.44
4.03
3.89
13.46
Target Price
N/A
6.0
N/A
1.0
7.5
129.41
31.83
112.57
372.2
Debt To Equity
N/A
N/A
0.053
0.003
0.036
6.2
0.067
0.01
0.6
Shares Owned By Institutions
N/A
9.41
N/A
18.02
82.46
81.07
89.22
75.48
91.44
Market Capitalization
558.34 K
10.86 K
2.23 M
2.24 M
387.98 M
4.78 B
10.39 B
5.86 B
7.53 B
Price To Earning
-0.12
N/A
12.33
-0.4
N/A
-3.34
48.17
-3.17
-13.96
Price To Earnings To Growth
N/A
N/A
N/A
N/A
-0.15
N/A
2.59
-0.03
N/A
Price To Sales
N/A
4.0E-4
0.51
27.98
1.97
14.13
4.99
N/A
98.01
Net Income
(2.54 M)
4.94 M
N/A
(22.55 M)
49.27 M
(239.24 M)
207.76 M
(85.89 M)
(373.63 M)
Earnings Per Share
-0.15
N/A
-0.13
-27.4
-3.82
-6.58
1.55
-0.94
-25.02
Shares Owned By Insiders
N/A
N/A
N/A
4.81
14.32
16.67
1.6
5.96
8.56
Revenue
N/A
6.03 M
4.05 M
420 K
380.79 M
270.6 M
1.83 B
N/A
N/A
Working Capital
(5.89 M)
(73 K)
2.12 M
(717 K)
382.62 M
365.41 M
923.68 M
348.09 M
518.73 M
Cash And Equivalents
61.27 K
26.49 M
870.3 K
29.08 M
206.68 M
73.39 M
1.53 B
155.02 M
211.77 M
Cash Per Share
N/A
0.98
0.25
2.32
3.53
1.82
4.77
2.02
12.38
Gross Profit
N/A
26.35 M
970.3 K
(455 K)
(74.21 M)
45.94 M
1.55 B
N/A
N/A
Day Typical Price
1.0E-4
1.0E-4
1.96
0.35
5.61
98.26
36.3
52.38
345.81
Accumulation Distribution
N/A
N/A
0.0051
0.0811
0.0775
0.0392
0.0251
0.0567
0.0323
Market Facilitation Index
N/A
N/A
0.01
0.03
0.45
3.94
0.92
3.07
11.38
Daily Balance Of Power
0.0
0.0
(1.00)
(0.67)
0.8667
(0.30)
0.837
(0.20)
(0.20)
Period Momentum Indicator
N/A
N/A
(0.01)
(0.02)
0.39
(1.18)
0.77
(0.60)
(2.27)
Rate Of Daily Change
1.0
1.0
0.99
0.94
1.07
0.99
1.02
0.99
0.99
Day Median Price
1.0E-4
1.0E-4
1.97
0.36
5.59
98.64
36.26
52.58
346.12
Price Action Indicator
N/A
N/A
(0.01)
(0.03)
0.27
(1.73)
0.51
(0.88)
(2.07)
Coefficient Of Variation
N/A
N/A
N/A
(495.45)
356.42
1349.78
430.93
(3,946)
801.53
Mean Deviation
N/A
N/A
N/A
5.21
4.31
1.79
1.45
3.56
2.67
Jensen Alpha
N/A
N/A
N/A
(1.62)
1.4
0.1042
0.4722
(0.31)
0.5166
Total Risk Alpha
N/A
N/A
N/A
(2.76)
0.6923
(0.21)
0.1698
(0.94)
(0.15)
Sortino Ratio
N/A
N/A
N/A
N/A
0.294
0.0277
0.3144
N/A
0.1818
Downside Variance
N/A
N/A
N/A
N/A
24.1
4.22
1.74
N/A
5.8
Standard Deviation
N/A
N/A
N/A
7.71
5.6
2.5
2.34
5.14
4.54
Kurtosis
N/A
N/A
N/A
2.48
1.84
2.5
12.9
4.32
13.47
Potential Upside
N/A
N/A
N/A
11.63
10.06
4.1
3.14
6.24
5.17
Treynor Ratio
N/A
N/A
N/A
(3.47)
1.18
0.2922
1.04
(0.1)
1.66
Maximum Drawdown
N/A
N/A
N/A
48.1
33.56
13.67
14.75
34.61
30.27
Variance
N/A
N/A
N/A
59.47
31.39
6.27
5.48
26.39
20.62
Market Risk Adjusted Performance
N/A
N/A
N/A
(3.46)
1.19
0.3022
1.05
(0.09)
1.67
Risk Adjusted Performance
N/A
N/A
N/A
(0.15)
0.2231
0.0636
0.1841
(0.01)
0.1037
Skewness
N/A
N/A
N/A
(0.16)
0.4208
0.9578
2.87
0.8567
3.11
Semi Deviation
N/A
N/A
N/A
N/A
4.02
1.91
0.8376
N/A
2.1
Information Ratio
N/A
N/A
N/A
(0.22)
0.2576
0.0227
0.1771
(0.05)
0.0964
Value At Risk
N/A
N/A
N/A
(15.66)
(6.13)
(3.78)
(1.77)
(8.05)
(3.96)
Expected Short fall
N/A
N/A
N/A
N/A
(5.11)
(2.19)
(1.80)
N/A
(3.67)
Downside Deviation
N/A
N/A
N/A
N/A
4.91
2.05
1.32
N/A
2.41
Semi Variance
N/A
N/A
N/A
N/A
16.14
3.65
0.7016
N/A
4.4

OncoVista Innovative Competition Performance Charts

Five steps to successful analysis of OncoVista Innovative Competition

OncoVista Innovative's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by OncoVista Innovative in relation to its competition. OncoVista Innovative's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of OncoVista Innovative in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact OncoVista Innovative's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to OncoVista Innovative, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your OncoVista Innovative position

In addition to having OncoVista Innovative in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Robots And Drones Thematic Idea Now

Robots And Drones
Robots And Drones Theme
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. The Robots And Drones theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Robots And Drones Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for OncoVista Pink Sheet Analysis

When running OncoVista Innovative's price analysis, check to measure OncoVista Innovative's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoVista Innovative is operating at the current time. Most of OncoVista Innovative's value examination focuses on studying past and present price action to predict the probability of OncoVista Innovative's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoVista Innovative's price. Additionally, you may evaluate how the addition of OncoVista Innovative to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY